GLP-1 Pipeline Update: February 2025 - Prime Therapeutics
GLP-1 Pipeline Update: February 2025
Quarterly view of the GLP-1 pipeline and anticipated indications
Prime Therapeutics’ GLP-1 Pipeline Update focuses on the development of GLP-1 receptor agonists, a class of drugs primarily used for managing diabetes and obesity. It provides updates on new therapies in the pipeline, their potential clinical benefits, and the implications for treatment options and health care costs.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.